Galecto Joins 2020's NASDAQ Gold Rush With $85m Launch
16 Biopharma IPOs In October
Executive Summary
Denmark-headquartered company’s lead candidate is an inhaled therapy for idiopathic pulmonary fibrosis.
You may also be interested in...
IPO Year In Review: Late Rally Gives 50 Newly Public Biopharma Firms A 45.1% Average Return
First-time offerings by drug developers fell from 2018 when 67 launched, but IPO investors’ fortunes improved with a year-end rally providing a 45.1% return versus a 7.5% loss in the prior year.
GSK Looks To Long-Acting Therapy To Restore Lead In HIV
GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.
COVID-19 Vaccine Makers Pledge Rapid Response To Omicron Threat
While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.